

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Jul 2026

Comparesion between treatment with Boswellia serrata against placebo to change the progression of cognitive disorders in Multiple sclerosis patients

Protocol summary

Summary

Multiple sclerosis is a demyelinating disease of central nervous system. Cognitive impairment is one of important disorder in these patients that have prevalence about 34-65%. Boswellia serrata is a substance that has been used for the augmentation of memory and learning skills in the past. There are plenty of studies focusing on the anti-inflammatory effects of Boswellia serrata. In addition of anti-inflammatory effects, neuroprotective properties have been reported. Since MS is an inflammatory disease and cognitive impairment is one of the influential elements on the life of MS patients, the effect of Boswellia serrata on the cognitive impairment of MS patients is investigated in the present work using BICAMS test.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013070813911N1**

Registration date: **2013-08-22, 1392/05/31**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2013-08-22, 1392/05/31

Registrant information

Name

Behnaz Sedighi

Name of organization / entity

Kerman University of Medical Sciences, Shafa hospital

Country

Iran (Islamic Republic of)

Phone

+98 34 1211 5817

Email address

b-sedighi@kmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran

Expected recruitment start date

2013-02-19, 1391/12/01

Expected recruitment end date

2013-06-22, 1392/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparesion between treatment with Boswellia serrata against placebo to change the progression of cognitive disorders in Multiple sclerosis patients

Public title

Effect of Boswellia serrata in prevention of cognitive impairment progression in multiple sclerosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criterion: definite multiple sclerosis. Exclusion criteria: taking new drugs; hypersensitivity to Boswellia serrata and drug side effect.

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 74

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Neurology Research Center, Kerman University of
Medical Sciences, Kerman, Iran

Street address

Shafa hospital, Kerman

City

Kerman

Postal code

Approval date

2013-02-13, 1391/11/25

Ethics committee reference number

K/91/379

Health conditions studied

1

Description of health condition studied

Multiple sclerosis

ICD-10 code

G35

ICD-10 code description

Multiple sclerosis

Primary outcomes

1

Description

Cognitive impairment

Timepoint

Before intervention and 2 months later

Method of measurement

BICAMS TEST

Secondary outcomes

empty

Intervention groups

1

Description

cap Boswellia serrata 300mg BD. 2 months for
intervention group

Category

Treatment - Drugs

2

Description

Cap placebo 300mg BD, 2 months for control group

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Infirmary multiple sclerosis, Shafa hospital

Full name of responsible person

Street address

Shafa hospital

City

Kerman

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Dr. Malekpur

Street address

Jomhuri Bool, Kerman University of Medical Science

City

Kerman

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kerman University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin
Type of organization providing the funding
empty

+98 34 1211 5780
Fax
Email
Behnaz.sedighi@gmail.com
Web page address

Person responsible for general inquiries

Contact

Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Behnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospita
City
Kerman
Postal code
Phone
+98 34 1211 5780
Fax
Email
Behnaz.sedighi@gmail.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Bhnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospital
City
Kerman
Postal code
Phone

Person responsible for updating data

Contact

Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Behnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospital
City
Kerman
Postal code
Phone
+98 34 1211 5780
Fax
Email
behnaz.sedighi@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty